We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mapping Genes Could Improve Cancer Diagnosis

By LabMedica International staff writers
Posted on 20 Jul 2017
Large-scale changes to the structure of the genome are often seen in cancer cells and scientists have found a way to detect these changes, which could enhance cancer diagnosis and aid the use of targeted treatments.

Chromosomal rearrangements occur constitutionally in the general population and somatically in the majority of cancers. More...
Detection of balanced rearrangements, such as reciprocal translocations and inversions, is troublesome, which is particularly detrimental in oncology where rearrangements play diagnostic and prognostic roles.

A team of medical scientists led by those at the Babraham Institute (Cambridge, UK) has developed a new application of a technique called Hi-C, which allows scientists to map how genetic material is arranged inside cells. By analyzing this information, investigators can reliably identify major genetic changes that other methods may miss. This all comes at a lower cost than standard DNA sequencing methods.

Hi-C can detect chromosome rearrangements, where large sections of DNA are exchanged or moved between pieces of the genome called chromosomes, and also copy number variation, where genetic material gets copied or deleted. Both of these changes can have drastic effects on how the cell behaves. The team used Hi-C to examine the genome of cancer cells from six people with brain tumors. They were able to identify major genome changes, often with pinpoint accuracy. Uniquely, this approach allows doctors and scientists to study genetic changes in the wider context of the whole genome. Hi-C could become a powerful tool for understanding the complex genetic changes found in many cancers.

The use of Hi-C on the six primary tumor samples revealed amplifications of known oncogenes, deletions of a tumor suppressor gene and many structural rearrangements, both balanced and unbalanced. One balanced rearrangement studied in detail was shown to result in the fusion of two genes known to be involved in cancer. Hi-C does not rely on the presence of dividing cells and can be used on all nucleated cell types. It is therefore a powerful tool in the analysis of solid tumors, where cytogenetic analysis is difficult and rarely performed as part of routine diagnosis/analysis, yet fusion genes can play a critical clinical role. Hi-C allows these tumors to be interrogated and provides a means to alleviate the bias in detection of both chromosomal rearrangements and fusion genes towards blood borne cancers.

Peter Fraser, PhD, a professor and the lead investigator of the study said, “Hi-C could play a pivotal role in the detection of chromosomal abnormalities and may aid the discovery of new fusion genes. The technique works with much lower quality samples than current techniques and has the additional advantage of being able to provide copy number information from the same data. This all comes at a significantly lower cost than standard methods that use DNA sequencing.” The study was published on June 27, 2017, in the journal Genome Biology.

Related Links:
Babraham Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.